Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen M Kuntz

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic modelElizabeth Bogard, Karen M Kuntz
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 28, 2014
Cost-effectiveness of second-generation antipsychotics for the treatment of schizophreniaTaehwan Park, Karen M Kuntz
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 18, 2003
A potential error in evaluating cancer screening: a comparison of 2 approaches for modeling underlying disease progressionSue J Goldie, Karen M Kuntz
Pharmacoeconomics|November 23, 2019
Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard RatioFernando Alarid-Escudero, Karen M Kuntz
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 13, 2002
Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity biasKaren M Kuntz, Sue J Goldie
International Journal of Cancer|February 7, 2012
How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysisUlrike Haug, Amy B Knudsen, Karen M Kuntz
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 1, 2022
CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness AnalysisFernando Alarid-Escudero, Deborah Schrag, Karen M Kuntz
Journal of the National Cancer Institute|July 18, 2014
Survival outcomes after contralateral prophylactic mastectomy: a decision analysisPamela R Portschy, Karen M Kuntz, Todd M Tuttle
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 2, 2013
Linear regression metamodeling as a tool to summarize and present simulation model resultsHawre Jalal, Bryan Dowd, François Sainfort, et al.
The Journal of Rheumatology|June 18, 2002
A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritisHyon K Choi, John D Seeger, Karen M Kuntz
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic modelElizabeth Bogard, Karen M Kuntz
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 28, 2014
Cost-effectiveness of second-generation antipsychotics for the treatment of schizophreniaTaehwan Park, Karen M Kuntz
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 18, 2003
A potential error in evaluating cancer screening: a comparison of 2 approaches for modeling underlying disease progressionSue J Goldie, Karen M Kuntz
Pharmacoeconomics|November 23, 2019
Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard RatioFernando Alarid-Escudero, Karen M Kuntz
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 13, 2002
Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity biasKaren M Kuntz, Sue J Goldie
International Journal of Cancer|February 7, 2012
How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysisUlrike Haug, Amy B Knudsen, Karen M Kuntz
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 1, 2022
CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness AnalysisFernando Alarid-Escudero, Deborah Schrag, Karen M Kuntz
Journal of the National Cancer Institute|July 18, 2014
Survival outcomes after contralateral prophylactic mastectomy: a decision analysisPamela R Portschy, Karen M Kuntz, Todd M Tuttle
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 2, 2013
Linear regression metamodeling as a tool to summarize and present simulation model resultsHawre Jalal, Bryan Dowd, François Sainfort, et al.
The Journal of Rheumatology|June 18, 2002
A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritisHyon K Choi, John D Seeger, Karen M Kuntz
Pageof 16